Zhejiang Wolwo Bio-Pharmaceutical Hits Day High with Strong 5.02% Surge

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has experienced a notable increase of 5.02% on July 1, 2026, reaching an intraday high of CNY 24.55. This performance stands out against the backdrop of the China Shanghai Composite, which only gained 0.44% on the same day. Over the past week, the stock has surged by 7.84%, while its monthly performance shows a rise of 5.88%. Despite a year-to-date decline of 13.62%, the company has demonstrated resilience with a 12.98% return over the past year, alongside a significant profit increase of 36.3%. The stock's current price reflects a Price to Book ratio of 3.60 and a Return on Equity of 14.93%. Additionally, the company boasts a high dividend yield of 1.17%, appealing to income-focused investors. Zhejiang Wolwo's operating cash flow reached a record CNY 396.16 million, and raw material costs have decreased by 6.14% year-over-year, indicating operational efficiency. As a large-cap player in the Pharmaceuticals & Biotechnology sector, the company continues to navigate a competitive landscape while maintaining a solid financial foundation.